Click image to enlargeA Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis.
Criteria:Participants must be at least 18 years of age inclusive, at the time of signing the informed consent.
Must be Diagnosed with
Participants must have documented history within 6 months prior to screening visit, of either inadequate response or inadvisability of topical treatments